Plant ID: NPO17539
Plant Latin Name: Ajuga decumbens
Taxonomy Genus: Ajuga
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
167911
Plant-of-the-World-Online:
n.a.
Analgesic; Anticoagulant; Depurative; Febrifuge; Haemostatic; Miscellany
China
TSHR; | |
ACHE; | |
TDP1; PKM; HSD17B1; NOX4; ALOX15; USP2; TNKS; TNKS2; | |
CFTR; | |
GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
AR; | |
ESR2; ESR1; | |
MAOA; PTGS2; XDH; | |
HIF1A; TP53; | |
ABCG2; ABCC1; | |
HTT; NPC1; MAPT; THPO; TTR; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.089E-10 | 7.134E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.529E-10 | 1.204E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.384E-09 | 3.070E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.142E-08 | 8.021E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-08 | 9.954E-06 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.190E-08 | 2.074E-05 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
MF | GO:0005488; binding | GO:0019899; enzyme binding | 5.462E-07 | 1.775E-04 | AR, CFTR, CYP1A1, CYP1A2, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, HTT, MAPT, PTGS2, SYK, TNKS2, TP53, USP2 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.630E-07 | 1.803E-04 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, HTT, MAPT, PKM, PTGS2, TP53, TTR, USP2, XDH |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 6.602E-07 | 1.997E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.070E-07 | 2.081E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 9.709E-07 | 2.547E-04 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 9.709E-07 | 2.547E-04 | GSK3B, HTT, MAPT |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.388E-06 | 6.768E-04 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, PTGS2, SYK, THPO, TSHR |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.377E-06 | 6.768E-04 | ESR1, ESR2 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 7.623E-06 | 1.407E-03 | CYP1A1, HIF1A, NOX4, PKM, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.727E-06 | 1.414E-03 | CYP1A1, CYP1A2, CYP1B1 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 8.038E-06 | 1.446E-03 | ABCG2, ACHE, AR, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, ESR1, ESR2, FLT3, GSK3B, HIF1A, HTT, MAOA, MAPT, NOX4, NPC1, PKM, PTGS2, SYK, TDP1, TNKS, TNKS2, TP53, XDH |
MF | GO:0005488; binding | GO:0002039; p53 binding | 8.534E-06 | 1.523E-03 | GSK3B, HIF1A, HTT, TP53 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.012E-05 | 1.722E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.012E-05 | 1.722E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.026E-05 | 1.732E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.277E-05 | 2.064E-03 | CYP1B1, GSK3B, HTT, MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.501E-05 | 2.318E-03 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 1.602E-05 | 2.448E-03 | AR, CSNK2A1, ESR1, GSK3B |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.686E-05 | 2.544E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.886E-05 | 2.813E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.022E-05 | 2.915E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.022E-05 | 2.915E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.022E-05 | 2.915E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.022E-05 | 2.915E-03 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 2.068E-05 | 2.963E-03 | CDK6, GSK3B, HIF1A, MAPT, PTGS2, SYK, TP53, XDH |
BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 2.537E-05 | 3.541E-03 | ACHE, CFTR, GSK3B, HIF1A, PTGS2, SYK, TP53 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.578E-05 | 3.576E-03 | ABCC1, ALOX15, SYK |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.841E-05 | 3.867E-03 | CSNK2A1, HIF1A, MAPT |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.365E-05 | 4.468E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 3.733E-05 | 4.867E-03 | ALOX15, AR, FLT3, NOX4, SYK, THPO, XDH |
BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 4.422E-05 | 5.534E-03 | ALOX15, PTGS2, SYK |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.743E-05 | 5.802E-03 | CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.042E-05 | 6.100E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.042E-05 | 6.100E-03 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 5.761E-05 | 6.781E-03 | ALOX15, ESR1, GSK3B, MAPT, TP53 |
MF | GO:0005488; binding | GO:0000166; nucleotide binding | 5.969E-05 | 6.875E-03 | ABCC1, ABCG2, CDK6, CFTR, CSNK2A1, FLT3, GSK3B, HSD17B1, NOX4, PKM, SYK, TP53, XDH |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 6.270E-05 | 7.038E-03 | AR, ESR1, GSK3B, TP53 |
BP | GO:0009987; cellular process | GO:0030154; cell differentiation | 6.440E-05 | 7.191E-03 | AR, CDK6, CYP1A1, ESR1, FLT3, GSK3B, HIF1A, MAPT, NOX4, PTGS2, THPO, TP53 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 7.051E-05 | 7.715E-03 | CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 7.051E-05 | 7.715E-03 | PKM, TTR |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 7.051E-05 | 7.715E-03 | ABCC1, ABCG2 |
MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 7.156E-05 | 7.791E-03 | ABCG2, ACHE, AR, FLT3, HIF1A, MAPT, PTGS2, TP53, TTR, XDH |
BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 7.994E-05 | 8.660E-03 | MAPT, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 9.195E-05 | 9.863E-03 | CFTR, CYP19A1, CYP1B1, NPC1 |
BP | GO:0032501; multicellular organismal process | GO:0048699; generation of neurons | 9.390E-05 | 9.925E-03 | CDK6, MAPT |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 9.390E-05 | 9.925E-03 | CYP1A1, CYP1A2 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.381E-04 | 2.017E-02 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
CC | Unclassified; | GO:0043234; protein complex | 2.859E-04 | 2.309E-02 | AR, CDK6, CFTR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, HTT, MAPT, PTGS2, SYK, TNKS, TP53, TTR |
CC | GO:0043226; organelle | GO:0000242; pericentriolar material | 6.283E-04 | 4.059E-02 | TNKS, TNKS2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.301E-10 | 1.029E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.827E-08 | 1.753E-06 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.713E-07 | 2.391E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.494E-07 | 1.444E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.850E-06 | 1.292E-04 | AR, GSK3B, CDK6, FLT3, PTGS2, HIF1A, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 6.249E-06 | 1.292E-04 | PKM, FLT3, TP53, HIF1A |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.806E-06 | 1.560E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.627E-05 | 5.738E-04 | PKM, MAOA, HSD17B1, CYP1A2, ALOX15, CYP1A1, PTGS2, CYP3A4, CYP19A1, XDH |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 5.861E-05 | 6.607E-04 | GSK3B, TP53, ESR1, HIF1A |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.018E-04 | 9.707E-04 | GSK3B, CDK6, CSNK2A1, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.895E-05 | 2.937E-04 | CYP1A2, ALOX15, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.805E-04 | 1.599E-03 | ABCC1, CDK6, CYP1B1, PTGS2, TP53 |
09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 6.742E-05 | 6.967E-04 | ABCC1, CFTR, ABCG2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 4.619E-04 | 2.921E-03 | GSK3B, SYK, CSNK2A1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.883E-04 | 2.921E-03 | CDK6, PKM, SYK, TP53 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.933E-04 | 2.020E-03 | GSK3B, ESR1, ESR2 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.167E-04 | 1.791E-03 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.586E-04 | 2.004E-03 | MAOA, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.469E-04 | 3.082E-03 | GSK3B, AR, TP53 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.814E-04 | 2.020E-03 | CYP3A4, CFTR, ABCG2 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 4.947E-04 | 2.921E-03 | CDK6, PTGS2, TP53 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.067E-03 | 5.512E-03 | MAOA, ALOX15, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 6.218E-04 | 3.352E-03 | SYK, CSNK2A1, PTGS2 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.430E-03 | 7.095E-03 | GSK3B, CDK6, TP53 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.139E-05 | 4.325E-04 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |